Cite

    Pagel, J. et al. (2022). Zandelisib with continuous or intermittent dosing as monotherapy or in combination with rituximab in patients with relapsed or refractory B-cell malignancy: a multicentre, first-in-patient, dose-escalation and dose-expansion, phase 1b trial. Lancet oncology. 23 (8), pp. 1021-1030. [Online].